English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Oral administration of 450191-S to humans at 4 mg/man led to the formation of the same plasma metabolites as those found in animals; i.e., M-1, M-2, M-A, M-3 and M-4. Unlike in animals, M-4 was the major metabolite in human plasma for 6 hr after dosing. 450191-S was not found in human plasma after administration of the commonly used dose of 450191-S (1-2 mg/man). The major human urinary metabolite was also M-4, and 44-68% of the dose was excreted as M-4 into 0-24 hr urine. The unchanged 450191-S excreted into the urine was scarcely detectable. Minor metabolites also seemed to be present in the urine, such as the 4OHM-3 conjugate, M-1 and its conjugate, M-2 and its conjugate, M-A and its conjugate, and M-3 and its conjugate. However, all of them together came to not more than 1% of the dose.

nihon yakurigaku zasshi/nihon yakurigaku zasshi

Pharmacology of a new sleep-inducer, 1H-1,2,4-triazolyl benzophenone derivative, 450191-S. (VIII). Examination and determination of metabolites in human plasma and urine.